
The Physical AI, Autonomous Systems And Robotics (PAI-ASR) Security Posture Management (SPM) Gap
getty
In March 2024, the cybersecurity world was rattled when it was revealed that XZ Utils, a popular open-source software (OSS) compression utility used across Linux distributions, had been quietly backdoored by a sophisticated threat actor. Over two years, an attacker posing as a helpful contributor gained maintainership rights, gradually inserting malicious code designed to grant remote shell access to compromised systems. This wasn't just a supply chain breach; it was a proof of concept for a new era of cyber threat operations: long-term, not detected and buried deep in the dependencies that modern infrastructure relies on.
Now imagine the same concept applied to the software stack of a surgical robot, an autonomous submarine or a port logistics AI system. In a world where Physical AI, Autonomous Systems and Robotics (PAI-ASR) often runs on stacks of OSS and pretrained models, the risks are greater than ever. We're no longer just talking about compromised servers—we're talking about compromised machines that make decisions in the physical world.
In boardrooms across the Defense, Healthcare, Maritime, Manufacturing and Energy sectors, executives are rapidly considering, piloting or deploying PAI-ASR systems that promise revolutionary advancements in efficiencies. Yet many independent security teams are struggling with an uncomfortable truth: These sophisticated machines remain dangerously vulnerable to attacks that could transform innovations into significant business risk overnight.
From automated cranes at global ports to select robotic procedures performed in operating rooms, we are witnessing a rapid and mass migration of AI into the physical world. PAI-ASRs are no longer niche or experimental. They're operational, essential and often invisible to the end user.
Defense agencies rely on AI-enabled drones for intelligence, surveillance, reconnaissance (ISR) and precision strikes. Shipping giants use robotic systems to manage logistics throughout maritime and ports operations. Hospitals are increasingly integrating autonomous systems and robotics to enhance patient care and streamline operations.
This is the promise of PAI-ASR: Machines that move, decide and scale. But the speed of innovation may be outpacing our ability to properly secure these systems from cyber and insider risks.
PAI-ASR systems are often tested and built from a soup of vulnerable components: OSS libraries like OpenCV and Robot Operating System (ROS), low-level firmware, pretrained AI models scraped from the internet and sensors subject to spoofing. Each layer introduces unique threats: supply chain compromises, insider threats, model inversion attacks—even adversarial patches that trick AI vision systems into seeing stop signs as speed limits.
A decade ago, in 2015, researchers at the University of Washington demonstrated how a surgical robot prototype could be compromised through network-based attacks, causing it to misbehave or shut down entirely. In real-world industrial environments, automation systems have been found exposed online, running unpatched Linux kernels with default credentials. In military settings, autonomous drones remain vulnerable to GPS spoofing and sensor manipulation. These aren't just IT risks; they're threats to operational integrity and physical safety.
The OSS ecosystem has revolutionized robotics and AI, but not without risk. OSS libraries like OpenCV power everything from defect detection in manufacturing to perception in autonomous vehicles, medical imaging and surgical robotics. They're flexible, fast and free. But packages like OpenCV, at a reported 2-3 million lines of code, depending on the build, are sprawling with broad contributor access and are often poorly maintained and inconsistently secured. Worse, these open source packages are often deeply embedded in critical systems, where malicious code could cascade into real-world harm.
Many PAI-ASR systems rely heavily on open source code written by volunteers or academic researchers who never thought their work would underpin military drones or surgical robots. There's often a lack of patch cadence and centralized oversight. Worse, many organizations don't understand or perform a risk assessment on the open source package's own software dependencies and imports.
That's a hacker's dream: critical systems built on complex, unaudited code, operated by organizations unaware of their own dependencies, creating a perfect storm of exploitable vulnerabilities.
Traditional IT security solutions weren't built for the unique challenges of PAI-ASR. When machines can move, make decisions and interact with the physical world, the SPM paradigm fundamentally changes.
PAI-ASR SPM isn't just vulnerability scanning or regulatory and compliance auditing. It's a risk-driven, holistic, contextual understanding of PAI-ASR attack surfaces.
PAI-ASR SPM methodologies, frameworks and platforms monitor and baseline the security state of PAI-ASR components, from low-level firmware to high-level decision logic. They identify drift in AI model performance. They detect anomalous behavior in PAI-ASR systems. They scan for source code vulnerabilities and dependency alerts in embedded code and verify that sensor inputs haven't been manipulated. Crucially, they do this continuously and not just once a year for a compliance checkbox.
We're entering a decade of PAI-ASR critical infrastructure. Military and defense, healthcare and MedTech, maritime and Ports—all of them will depend on machines that make decisions humans don't directly control. If those machines are compromised, the results won't be confined to cyberspace. We're talking about hospital mishaps, disrupted logistics supply chains and negatively impacted defense capabilities.
PAI-ASR SPM companies don't eliminate risk, but they can redefine how it's managed. These firms bring domain expertise, mission alignment, real-time visibility and operational resilience to one of the most complex engineering challenges of our time.
We're engineering PAI-ASR systems at an unprecedented pace—machines that are faster and more autonomous than most could have imagined just a decade ago. But while their capabilities have evolved rapidly, our SPM paradigms haven't kept up. The next decade won't be defined by innovation alone but by whether we can properly secure and minimize risk to the confidentiality, integrity and availability of PAI-ASR systems.
PAI-ASR SPM isn't a luxury. It is fundamentally necessary.
Forbes Technology Council is an invitation-only community for world-class CIOs, CTOs and technology executives. Do I qualify?
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Ondas Appoints Dr. Irit Idan to Advisory Board of Ondas Autonomous Systems
Former Rafael Advanced Systems Executive and SoftBank Vision Fund Advisor Brings Deep Expertise in AI, Robotics, Autonomous Systems, and Defense Innovation Dr. Idan's appointment supports OAS' broader growth plan and long-term strategy to enhance its product roadmap, strengthen customer relationships, and accelerate global adoption of its Optimus and Iron Drone Raider platforms BOSTON, MA / / August 15, 2025 / Ondas Holdings Inc. (NASDAQ:ONDS) ("Ondas" or the "Company"), a leading provider of private industrial wireless networks and commercial drone and automated data solutions, today announced the appointment of Dr. Irit Idan to the OAS Advisory Board. Dr. Idan will serve alongside Yaniv Rotem as the second member of this select group, guiding OAS in advancing its leadership in autonomous defense, homeland security, and critical infrastructure protection. Dr. Idan is a recognized leader in technology-driven transformation, advising on the integration of AI, robotics, autonomous systems, medical devices, defense technologies, and more to drive industry innovation and economic growth. She previously served as Executive Vice President for Research and Development at RAFAEL - Advanced Defense Systems Ltd., the Israeli government-owned defense company and developer of the world-renowned Iron Dome missile defense system. At RAFAEL, she led multi-billion-dollar R&D programs in defense, space, and air superiority systems, advancing the company's position as a global leader in breakthrough technologies. Dr. Idan later served as an investment advisor for the SoftBank Vision Fund, one of the largest technology investment funds in the world with over $100 billion in committed capital. The fund is known for backing transformative companies in AI, robotics, autonomous systems, telecommunications, and other deep technologies. In this role, Dr. Idan helped due diligence in global investment and identify disruptive technologies. "We are honored to welcome Dr. Idan to the OAS Advisory Board," said Eric Brock, Chairman and CEO of Ondas. "Her experience leading innovation at the highest levels of the defense industry and advising global technology investments will be invaluable as we expand OAS' role in delivering next-generation autonomous systems for defense and homeland security. Dr. Idan's track record in driving breakthrough programs aligns perfectly with our mission to deliver operationally proven, AI-powered solutions to our customers worldwide." "OAS is building a portfolio of systems that are redefining what is possible in autonomous defense and security," said Oshri Lugassy, Co-CEO of Ondas Autonomous Systems. "Dr. Idan brings rare expertise across defense technology development, global strategy, and commercialization of advanced systems. We believe her insight will strengthen our ability to innovate, scale, and deliver solutions that address the urgent and evolving needs of our customers." Dr. Idan began her career in astrophysics research, earning a Ph.D. from the Technion - Israel Institute of Technology. She is the recipient of multiple prestigious fellowships, including the Amelia Earhart Fellowship for Research Excellence in Aerospace Science (three consecutive years), the Minerva Fellowship for German-Israeli academic exchange, and the Katzir Fellowship from Israel's Prime Minister's Office. She has served on the Board of Directors of multiple technology companies, is a member of the Technion Council and International Board of Governors and was a senior member of Israel's Grand Strategy Forum, advising the President of Israel on national security and strategic policy. Her appointment supports OAS' broader growth plan outlined in recent reports, which calls for expanding its advisory network to include globally recognized leaders in defense, deep tech, and autonomous systems. This initiative is part of Ondas' long-term strategy to enhance its R&D vision, strengthen customer relationships, and accelerate global adoption of its Optimus and Iron Drone Raider platforms. About Ondas Holdings Holdings Inc. (NASDAQ:ONDS) is a leading provider of autonomous drone and private wireless solutions through its business units Ondas Autonomous Systems (OAS) and Ondas Networks. Ondas' technologies offer a powerful combination of aerial intelligence and next-generation connectivity to enhance security, operational efficiency, and data-driven decision-making across essential industries. OAS offers a portfolio of best-in-class AI-driven defense and security drone platforms that are currently deployed globally to protect and secure sensitive locations, populations, and critical infrastructure. Operating via its wholly owned subsidiaries, American Robotics and Airobotics, OAS offers the Optimus System-the first U.S. FAA-certified sUAS for automated aerial security and data capture-and the Iron Drone Raider-an autonomous counter-UAS system designed to neutralize hostile drones. Ondas Networks provides software-defined wireless broadband technology through its FullMAX platform, based on the IEEE 802.16t standard. This standards-based system delivers high-performance connectivity for mission-critical IoT applications in markets such as rail, utilities, oil and gas, transportation, and government. For additional information on Ondas Holdings: X and LinkedIn For Ondas Autonomous Systems: LinkedInFor Airobotics: X and LinkedInFor American Robotics: X and LinkedInFor Ondas Networks: X and LinkedIn Forward-Looking StatementsStatements made in this release that are not statements of historical or current facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance, or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including the risks discussed under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of our most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of our Quarterly Reports on Form 10-Q and in our other filings with the SEC. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as required by law. ContactsIR Contact for Ondas Holdings Inc.888-657-2377ir@ Media Contact for OndasEscalate PRondas@ Preston GrimesMarketing Manager, Ondas Holdings SOURCE: Ondas Holdings Inc. View the original press release on ACCESS Newswire Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 hours ago
- Yahoo
Elutia Inc (ELUT) Q2 2025 Earnings Call Highlights: Strong EluPro Growth Amid Financial Challenges
BioEnvelope Revenue: Up 33% year over year, reaching a $14 million run rate. EluPro Growth: 49% sequential growth for the quarter, now comprising 68% of BioEnvelope revenue. Hospital Systems: 161 hospital systems actively ordering EluPro. Sales Performance: EluPro sales per account are 130% higher than CanGaroo. Distributor Network: 1,099 distributors, contributing 33% of total sales. Boston Scientific Partnership: Involved in 98 hospitals, facilitating 30% of EluPro cases. Total Quarterly Sales: $6.3 million for the quarter. Gross Margin: Adjusted gross margin at 62.4% for Q2, up over 4 percentage points from a year ago. Adjusted EBITDA: $3.8 million loss for the quarter. Cash Position: Ended Q2 with $8.5 million in cash. Warning! GuruFocus has detected 5 Warning Signs with ELUT. Release Date: August 14, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Elutia Inc (NASDAQ:ELUT) reported a 49% sequential growth in EluPro sales, driven by securing seven national GPO contracts and expanding into 161 hospital systems. The company has developed a strong partnership with Boston Scientific, which is actively involved in EluPro sales in 98 hospitals, facilitating 30% of EluPro cases. Elutia Inc (NASDAQ:ELUT) has achieved significant recognition for its drug-eluting technology, winning multiple awards including the Edison Award and Medical Device Network Excellence Awards. The company is making substantial progress in the breast reconstruction market with its NXT-41x platform, aiming to address significant unmet medical needs. Elutia Inc (NASDAQ:ELUT) has settled 97 out of 110 lawsuits related to a past product recall, reducing legal expenses and removing a significant overhang on the company. Negative Points Elutia Inc (NASDAQ:ELUT) faces challenges in scaling VAC approvals, which are crucial for revenue growth, with a current target of 1,600 hospital centers. The company is still dealing with 13 unresolved lawsuits from a past product recall, which continue to pose a potential financial and reputational risk. SimpliDerm sales have underperformed, generating $2 million in revenue, which is lower than previous quarters. Elutia Inc (NASDAQ:ELUT) reported a $3.8 million adjusted EBITDA loss for the quarter, indicating ongoing financial challenges despite revenue growth. The company has $8.5 million in cash, which may be insufficient for future growth initiatives without successful business development transactions. Q & A Highlights Q: What are the current bottlenecks for EluPro's growth, and how is Elutia addressing them? A: C. Randal Mills, CEO, explained that initially, the commercial team challenged the operations team to keep up with production, but they have since mastered it, as reflected in improved gross margins. The main focus now is scaling VAC approvals, as revenue growth is directly tied to the number of hospitals ordering EluPro. The company is targeting 1,600 centers and maintains a strong pipeline of VAC submissions, with Boston Scientific aiding in opening new accounts. Q: Can you provide more details on the NXT-41 development timeline and its relation to SimpliDerm? A: C. Randal Mills, CEO, stated that the NXT-41 platform will be launched in two phases: the base matrix in the second half of 2026 and the drug-eluting version in the first half of 2027. The base matrix is a new engineered product, not derived from SimpliDerm, designed to eliminate donor variability. SimpliDerm helps establish key accounts and relationships, but NXT-41 aims to offer a more complete solution. Q: How soon can we expect updates on business development activities? A: C. Randal Mills, CEO, mentioned that while nothing is finalized, they expect to conclude at least one transaction in the coming weeks or quarters. He emphasized the importance of not rushing the process to ensure quality outcomes. Q: What are the prospects for maintaining or expanding gross margins, especially with cardiovascular products back in the mix? A: Matthew Ferguson, CFO, highlighted opportunities for gross margin improvement across all segments. EluPro's scaling will enhance margins, cardiovascular products already have high margins over 80%, and there are efficiency improvements possible with SimpliDerm. Q: What level of clinical evidence is needed for FDA approval of NXT-41's base matrix and drug-eluting version? A: C. Randal Mills, CEO, explained that both versions will follow the same regulatory pathway as EluPro, involving the Center for Device and Radiologic Health and the Center for Drugs. The staggered launch allows for clinical data generation to support long-term success, with the base matrix proving its efficacy before adding the drug-eluting component. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10 hours ago
- Yahoo
Rocket Lab's Electron Strengthens Grip on Small Launch Market
Rocket Lab USA, Inc. (RKLB) has emerged as an industry forerunner in the launch and space systems market. In the launch segment, Rocket Lab has built a strong position through its small satellite launch services offered by the Electron rocket, which is currently the second most frequently launched U.S. rocket. The growing demand for Rocket Lab's services involving its Electron rocket is evident from several recent developments. In February 2025, the company secured a major contract from a Japan-based Earth imaging company, iQPS. This agreement covers eight dedicated Electron launches, with six missions scheduled for 2025 and two in 2026, making it one of the largest Electron launch deals to date. In June, RKLB successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. In the same month, Rocket Lab got selected to launch a dedicated Electron mission for the European Space Agency (ESA) for the first time, to deploy the first pair of satellites for a future navigation constellation for Europe. Rocket Lab will conduct these launches, no earlier than December 2025. With such high-profile contracts in its order book, Rocket Lab's Electron rocket cements its dominance in the small launch market, proving its reliability and scalability as the demand for dedicated, agile satellite deployment grows. Other Stocks to Keep on the Watchlist In the modern era of space exploration, factors such as rapid technological advancements, rising demand for satellite deployment, increasing commercial space activities and growing investment in space infrastructure are driving the expansion of the space launch services market. Apart from RKLB, other industry players like Boeing (BA) and Lockheed Martin (LMT), which already have a well-established presence in the launch services sector, are also positioned to benefit from these growth trends. Their joint venture, the United Launch Alliance (ULA), has been a key U.S. launch provider, successfully delivering more than 150 Atlas and Delta rockets since its formation in 2006. ULA's latest offering, the Vulcan rocket, is an evolution of the Atlas V and Delta IV vehicles. It is designed to provide more affordable and accessible launch options for a variety of missions, further strengthening ULA's competitive standing in the market. RKLB's Price Performance, Valuation and Estimates Shares of RKLB have gained 637.6% in the past year compared with the industry's 43.3% growth. Image Source: Zacks Investment Research The company shares are expensive on a relative basis, with its forward 12-month Price/Sales being 26.45X compared with its industry's average of 10.16X. Image Source: Zacks Investment Research The Zacks Consensus Estimate for RKLB's 2025 loss has improved over the past 60 days. Image Source: Zacks Investment Research RKLB stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report The Boeing Company (BA) : Free Stock Analysis Report Lockheed Martin Corporation (LMT) : Free Stock Analysis Report Rocket Lab Corporation (RKLB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data